Medidata Unveils AI-Powered Imaging Solution to Accelerate Clinical Trial Analysis
Advertisement
The company said the upgraded capabilities are designed to reduce imaging-related delays and improve the speed and accuracy of clinical trial data analysis.
Medidata, a Dassault Systèmes brand focused on clinical trial technology, has launched an enhanced AI-powered imaging solution within its Medidata Data Experience platform at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The company said the upgraded capabilities are designed to reduce imaging-related delays and improve the speed and accuracy of clinical trial data analysis.
The new solution integrates artificial intelligence into imaging workflows across the clinical data lifecycle, targeting challenges commonly faced in oncology and other image-intensive studies.
According to Medidata, the platform can deliver a 32% faster protected health information (PHI) redaction process through an automated text detection algorithm, reducing the need for manual review. The company also reported that its AI-powered anatomy verification capabilities achieve more than 97% accuracy, exceeding industry benchmark levels.
In addition, Medidata announced upcoming intelligent quality control features that will provide near real-time validation of imaging data. The functionality will use “patient similarity” checks to verify patient identity, confirm the presence of IV or oral contrast, and assess whether the correct field of view has been captured. The company said the capability is intended to help study teams identify and address imaging issues before they result in delays.
“Imaging provides the pivotal, objective proof required to determine a treatment's efficacy,” said Wayne Walker, Senior Vice President, Data Experience at Medidata. He noted that AI is being embedded across the company’s technology portfolio to improve the speed and quality of clinical research processes.
The launch comes as imaging continues to play a critical role in oncology research. Medidata stated that tumor progression serves as the primary endpoint in more than 90% of oncology clinical trials, making imaging data central to treatment evaluation and regulatory decision-making.
Looking ahead, the company plans to introduce additional AI-driven imaging capabilities next year. These include a specialist interface and one-click image transfer functionality leveraging Medidata’s network of more than 1,000 hospitals across the United States.
The new imaging capabilities were unveiled during demonstrations at ASCO 2026, where Medidata is showcasing its latest clinical trial technologies.
Stay tuned for more such updates on Digital Health News
